UY37798A - Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil - Google Patents

Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil

Info

Publication number
UY37798A
UY37798A UY0001037798A UY37798A UY37798A UY 37798 A UY37798 A UY 37798A UY 0001037798 A UY0001037798 A UY 0001037798A UY 37798 A UY37798 A UY 37798A UY 37798 A UY37798 A UY 37798A
Authority
UY
Uruguay
Prior art keywords
betahistine
dissolves
weight
hours
betahistina
Prior art date
Application number
UY0001037798A
Other languages
English (en)
Inventor
Sunil Shantwan Borude
Vinod Purushottam Dube
Venkata Ramana Naidu
Himanshukumar Dasharathlal Patel
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59829185&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37798(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of UY37798A publication Critical patent/UY37798A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a una composición de liberación prolongada 24 horas no pulsátil sólida y oral que comprende una cantidad de betahistina o de una sal farmacéuticamente de la misma, equivalente a 48 mg de diclorhidrato de betahistina, junto con uno o más excipientes o vehículos farmacéuticamente aceptables, en el que la composición exhibe un perfil de disolución según el cual: hasta el 30 % en peso de betahistina se disuelve en 1 hora; de 35% a 45% en peso de betahistina se disuelve en 2 horas; de 46% a 60% en peso de betahistina se disuelve en 4 horas; de 61% a 80% en peso de betahistina se disuelve en 8 horas; de 81 % a 97% en peso de betahistina se disuelve en 16 horas; y de 98 % a 100 % en peso de betahistina se disuelve en 24 horas. También se refiere a su uso en terapia, particularmente en el tratamiento de una afección o enfermedad vestibular, más particularmente en el tratamiento de la enfermedad de Ménière.
UY0001037798A 2017-07-20 2018-07-05 Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil UY37798A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721025857 2017-07-20
EP17189264.9A EP3431078B1 (en) 2017-07-20 2017-09-04 Non-pulsatile prolonged-release betahistine oral solid compositions

Publications (1)

Publication Number Publication Date
UY37798A true UY37798A (es) 2019-01-02

Family

ID=59829185

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037798A UY37798A (es) 2017-07-20 2018-07-05 Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil

Country Status (22)

Country Link
US (1) US11433058B2 (es)
EP (2) EP3431078B1 (es)
JP (1) JP7084950B2 (es)
CN (1) CN110891551A (es)
AR (1) AR112281A1 (es)
AU (1) AU2018302771B2 (es)
BR (1) BR112020000977A2 (es)
CA (1) CA3069282A1 (es)
CL (1) CL2020000124A1 (es)
CO (1) CO2020001742A2 (es)
DK (1) DK3431078T3 (es)
ES (1) ES2862209T3 (es)
HR (1) HRP20210570T1 (es)
LT (1) LT3431078T (es)
MX (1) MX2020000702A (es)
PH (1) PH12020500001A1 (es)
PL (1) PL3431078T3 (es)
PT (1) PT3431078T (es)
SA (1) SA520411067B1 (es)
UY (1) UY37798A (es)
WO (1) WO2019016668A1 (es)
ZA (1) ZA202000030B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115266955B (zh) * 2021-04-29 2024-10-01 景忠山国药（唐山）有限公司 基于一测多评法的耳聋胶囊中成分含量的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1309591B1 (it) * 1999-03-05 2002-01-24 Formenti Farmaceutici Spa Composizioni a rilascio controllato di betaistina.
EP1414458B1 (en) * 2001-07-06 2007-04-11 Endo Pharmaceuticals Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
ATE395048T1 (de) * 2003-07-04 2008-05-15 Formenti Farmaceutici Spa Betahistinezubereitungen mit kontrollierter freisetzung
WO2012131722A1 (en) * 2011-03-30 2012-10-04 Sun Pharma Advanced Research Company Ltd. Controlled release composition of betahistine
DE102012105528A1 (de) 2012-06-25 2014-01-02 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur Freisetzung von Wirkstoffen
WO2014174073A1 (en) * 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib

Also Published As

Publication number Publication date
EP3654954A4 (en) 2021-06-16
AU2018302771B2 (en) 2022-05-12
CO2020001742A2 (es) 2020-02-28
EP3654954A1 (en) 2020-05-27
BR112020000977A2 (pt) 2020-07-14
LT3431078T (lt) 2021-05-10
CA3069282A1 (en) 2019-01-24
JP7084950B2 (ja) 2022-06-15
SA520411067B1 (ar) 2022-09-28
US20210161871A1 (en) 2021-06-03
CN110891551A (zh) 2020-03-17
ZA202000030B (en) 2021-08-25
PH12020500001A1 (en) 2020-09-14
HRP20210570T1 (hr) 2021-09-03
DK3431078T3 (da) 2021-04-19
RU2020101925A (ru) 2021-08-20
US11433058B2 (en) 2022-09-06
EP3431078B1 (en) 2021-01-20
MX2020000702A (es) 2020-10-14
ES2862209T3 (es) 2021-10-07
WO2019016668A1 (en) 2019-01-24
EP3431078A1 (en) 2019-01-23
CL2020000124A1 (es) 2020-09-21
JP2020528045A (ja) 2020-09-17
PT3431078T (pt) 2021-04-21
AR112281A1 (es) 2019-10-09
RU2020101925A3 (es) 2021-08-27
PL3431078T3 (pl) 2021-07-12
AU2018302771A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
UY37998A (es) Agentes antivirales contra la hepatitis b
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
NI201200089A (es) INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA.
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
JP2010222367A5 (es)
EA201490254A1 (ru) Комбинированное лечение гепатита с
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
CY1113726T1 (el) Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2016011297A3 (en) Methods and related compositions for improved drug bioavailability and disease treatment
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CL2020000124A1 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil.
PE20171061A1 (es) Composiciones farmaceuticas de accion prolongada para hepatitis c
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20240826